A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer

Trial Profile

A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Pyrotinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 07 Jun 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016.
    • 12 Dec 2015 Status changed from active, no longer recruiting to completed, as per results presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top